Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Wenqiang Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Drug Resistance, Neoplasm, Androgen Receptor Antagonists, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: China Pharmaceutical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Bifunctional agents that simultaneously antagonize and degrade various AR proteins more effectively block the AR signaling pathway, offering a promising strategy for the treatment of mCRPC patients. Herein, we report the discovery and development of a series of small-molecule AR degraders with 3,8-diazabicyclo[3.2.1]octan scaffold. The optimal compound 20i exhibited potent AR antagonistic and degrading activities, effectively overcoming multiple resistance mechanisms and showing significant antiproliferative effects against enzalutamide-resistant PCa cell lines. Moreover, compound 20i exhibited favorable oral pharmacokinetics and a good safety profile. In the 22Rv1 xenograft models, 20i exhibited potent antitumor activity without obvious toxicity. Taken together, these results demonstrated that 20i might be a potential candidate for the treatment of enzalutamide-resistant PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
- State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Pharmaceutical Co., Ltd, 699-18 Xuan Wu Avenue, Nanjing 210042, China.
- Jiangsu Simcere Pharmaceutical Co., Ltd, 699-18 Xuan Wu Avenue, Nanjing 210042, China.
- Department of pharmacy, Youjiang Medical University for Nationalities, No. 98 ChengXiang Road, Youjiang, Baise 533000, Guangxi Zhuang Autonomous Region, China.
ORCID-Profile: Yadong Chen, Yu Jiao
Förderung
- China Pharmaceutical University
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Zhu, H., Chen, Z., Li, H., Chen, X., Fan, Y., Zhou, X., Luo, Y., Zhang, Y., Tang, F., Zhang, X., Feng, Y., Lu, T., Wei, X., Chen, Y., Chen, C., & Jiao, Y. (2025). Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03043
Vancouver
Zhang W, Zhu H, Chen Z, Li H, Chen X, Fan Y, et al. Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03043
BibTeX
@article{Zhang2025,
author = {Zhang, Wenqiang and Zhu, Hao and Chen, Zhuolin and Li, Hongmei and Chen, Xingru and Fan, Yawen and Zhou, Xiaoyu and Luo, Yi and Zhang, Yan and Tang, Feng and Zhang, Xinhao and Feng, Yunrui and Lu, Tao and Wei, Xian and Chen, Yadong and Chen, Caiping and Jiao, Yu},
title = {Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03043}
}
EUVIMED